TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06906380: A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

Sponsor: ARCE Therapeutics, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 49 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$12,335,400

Rescue Site Savings

+$8,131,200

Unlock Full NCT06906380 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06906380 Rescue Dossier →